InflaRx N.V. (NASDAQ:IFRX) Sees Large Increase in Short Interest

InflaRx N.V. (NASDAQ:IFRX) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totaling 758,400 shares, an increase of 67.3% from the August 31st total of 453,200 shares. Based on an average daily trading volume, of 529,300 shares, the short-interest ratio is currently 1.4 days. Based on an average daily trading volume, of 529,300 shares, the short-interest ratio is currently 1.4 days.

InflaRx Stock Down 8.6%

Shares of NASDAQ IFRX opened at $1.38 on Wednesday. The company’s fifty day moving average is $1.19 and its 200-day moving average is $1.14. The stock has a market cap of $92.64 million, a price-to-earnings ratio of -1.72 and a beta of 1.40. InflaRx has a twelve month low of $0.71 and a twelve month high of $2.82.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.24). The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.02 million. On average, research analysts anticipate that InflaRx will post -1.04 EPS for the current fiscal year.

Institutional Investors Weigh In On InflaRx

Institutional investors have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. acquired a new stake in InflaRx in the 2nd quarter valued at $262,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of InflaRx by 158.3% during the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock worth $118,000 after purchasing an additional 91,927 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new position in InflaRx in the 2nd quarter valued at about $65,000. Woodline Partners LP acquired a new position in InflaRx in the 1st quarter valued at about $766,000. Finally, 683 Capital Management LLC grew its stake in InflaRx by 26.8% in the 1st quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock valued at $2,678,000 after buying an additional 555,000 shares during the last quarter. 42.39% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on IFRX shares. HC Wainwright began coverage on shares of InflaRx in a research note on Tuesday, September 2nd. They issued a “buy” rating and a $6.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a report on Saturday, September 27th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.20.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.